Aprea Therapeutics Inc (APRE)

Apr 04, 2025

APRE stock touches 52-week low at $1.74 amid market challenges - Investing.com

Apr 04, 2025

Apr 04, 2025

Aprea Therapeutics President/CEO Gilad Oren Acquires 5,500 Shares - TradingView

Apr 04, 2025

Apr 04, 2025

Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock - Investing.com

Apr 04, 2025

Apr 03, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Apr 03, 2025

Apr 02, 2025

Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN

Apr 02, 2025

Apr 01, 2025

Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo

Apr 01, 2025

Apr 01, 2025

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World

Apr 01, 2025

Mar 31, 2025

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView

Mar 31, 2025

Mar 31, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 31, 2025

Mar 29, 2025

Brokers Issue Forecasts for APRE FY2025 Earnings - Defense World

Mar 29, 2025

Mar 28, 2025

Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN

Mar 28, 2025

Mar 28, 2025

What is Wedbush’s Estimate for APRE FY2029 Earnings? - Defense World

Mar 28, 2025

Mar 27, 2025

APRE stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

APRE stock touches 52-week low at $2.15 amid market challenges - Investing.com India

Mar 27, 2025

Mar 26, 2025

Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World

Mar 26, 2025

Mar 26, 2025

Aprea Therapeutics Advances Cancer Trials Amid Financial Progress - TipRanks

Mar 26, 2025

Mar 25, 2025

Aprea Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 25, 2025

APREA THERAPEUTICS Earnings Results: $APRE Reports Quarterly Earnings - Nasdaq

Mar 25, 2025

Mar 25, 2025

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Mar 25, 2025

Mar 21, 2025

Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo

Mar 21, 2025

Mar 18, 2025

Aprea Therapeutics (APRE) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 18, 2025

Mar 13, 2025

Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MyChesCo

Mar 13, 2025

Mar 12, 2025

MD Anderson to explore Aprea’s WEE1 kinase inhibitor for HNSCC - BioWorld Online

Mar 12, 2025

Mar 11, 2025

Aprea Therapeutics partners with MD Anderson for cancer study - Investing.com India

Mar 11, 2025

Mar 11, 2025

Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc) - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Aprea Therapeutics partners with MD Anderson for cancer study By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 11, 2025

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - The Manila Times

Mar 11, 2025

Mar 07, 2025

Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MSN

Mar 07, 2025

Mar 03, 2025

Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MSN

Mar 03, 2025

Feb 26, 2025

Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World

Feb 26, 2025

Feb 12, 2025

Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St

Feb 12, 2025

Feb 07, 2025

Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN

Feb 07, 2025

Feb 07, 2025

Aprea Therapeutics expands cancer drug patent portfolio - MSN

Feb 07, 2025

Feb 07, 2025

Ault Global (NYSEAMERICAN:DPW) Enters into Exchange Agreement with Orchid Finance LLC – Converts Outstanding Term Note for Convertible Promissory NoteThe financial landscape of Ault Global, trading under the ticker symbol DPW on the NYSE Amer - Defense World

Feb 07, 2025

Feb 07, 2025

Aprea Therapeutics Announces Update to Patent Portfolio in DNA Damage Response Cancer TherapeuticsDOYLESTOWN, PA, February 5, 2025 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) provided an update on its existing patent portf - Defense World

Feb 07, 2025

Feb 06, 2025

FDA Greenlights Aprea Therapeutics' Investigational New Drug Application for Novel Cancer Treatment - MSN

Feb 06, 2025

Feb 06, 2025

Aprea Therapeutics provides update on existing patent portfolio - Yahoo Finance

Feb 06, 2025

Feb 05, 2025

Aprea Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com South Africa

Feb 05, 2025

Feb 05, 2025

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times

Feb 05, 2025

Jan 21, 2025

Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034 | DelveInsight - The Globe and Mail

Jan 21, 2025

Jan 21, 2025

APRE News Today | Why did Aprea Therapeutics stock go up today? - MarketBeat

Jan 21, 2025

Jan 20, 2025

Aprea Therapeutics Discloses Unaudited Financials and Updates Corporate PresentationAprea Therapeutics, Inc. recently released an updated corporate presentation, alongside disclosing financial information as of December 31, 2024. The company shared - Defense World

Jan 20, 2025

Jan 20, 2025

StockNews.com Begins Coverage on SenesTech (NASDAQ:SNES) - Defense World

Jan 20, 2025

Jan 17, 2025

H.C. Wainwright sets target on Aprea stock, Buy rating on clinical update - MSN

Jan 17, 2025

Jan 17, 2025

HC Wainwright Reiterates Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World

Jan 17, 2025